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INTRODUCTION
Ovarian cancer is the leading cause of death from gyne  co­
logic malignancies [1]. A retrospective study by Griffiths [2] 
in 1975 demonstrated a strong association between post­
operative largest residual tumor and survival. Since then, initial 
cytoreductive (debulking) surgery and adjuvant chemother­
apy has become the standard of care in advanced epithelial 
ovarian cancer [3­5].
Currently the treatment concept of neoadjuvant chemo­
therapy has been introduced. In this alternative management 
approach the initial treatment in some advanced ovarian car­
cinoma patients usually consists of 3 courses of chemo  therapy 
followed by cytoreductive surgery (interval debulking) and 
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Objective: To assess whether there is an association between improvement of computed tomography imaging results prior to 
interval debulking with survival in patients treated by neoadjuvant chemotherapy.
Methods: The clinical and outcome data of all advanced ovarian, primary peritoneal and tubal carcinoma patients who after 
diagnosis had neoadjuvant chemotherapy and underwent interval debulking during the period 2000­2010, were abstracted. 
Results of computed tomography imaging at diagnosis and prior to interval debulking were compared. Two parameters were 
assessed: the change of the size and number of abnormal findings and the change in the amount of ascites. CA­125 level 
response was also calculated. An assessment of progression free survival and of survival by the Kaplan­Meier method was made 
according to the change in computed tomography imaging results and according to response of CA­125 levels.
Results: The median progression free survival and the median survival of the 37 study group patients were 7.9 and 49.2 months 
respectively. No significant difference in progression free survival and survival was observed between patients with marked 
improvement in the computed tomography results and those with less desirable results (7.93 vs. 7.23 months respectively, 
p=0.89; 45.8% vs. 52.5% months respectively, p=0.95). There were also no statistically significant difference according to CA­125 
level response.
Conclusion:  It seems that neither improvement in imaging results nor CA­125 level response can predict the survival of ovarian 
carcinoma patients prior to interval debulking after neoadjuvant chemotherapy.
Keywords: Imaging results, Interval debulking, Neoadjuvant chemotherapy, Ovarian carcinoma, Survival prediction
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additional three courses of postoperative chemotherapy. Pro­
posed advantages of neoadjuvant chemotherapy include an 
increased rate of optimal residual disease, less extensive sur­
gery, reduced blood loss, lower morbidity, shortened hospital 
stay and improved quality of life.
Neoadjuvant chemotherapy may also act as a mechanism 
to select out patients with platinum­resistant disease. While 
still controversial, it has been found in many retrospective and 
prospective studies that the outcome after the neoadjuvant 
approach is not inferior to that after initial cytoreductive sur­
gery [6­9].
Various noninvasive means have been proposed to predict 
cytoreduction inability for the selection of patients in whom 
the neodjuvant approach is more appropriate. These include 
various computed tomography (CT) criteria [10­12] clinical 
and CA­125 level criteria [13,14]. 
A few investigations deal with the ability to predict progression 
free survival (PFS) and overall survival prior to interval debul­
king [15­ 18]. Most of them are by assessment of CA­125 level 
reduction [15­17]. Up to now no reliable prediction method 
has been found.
The purpose of the present study was to assess whether 
there is an association between improvement of CT imaging 
results prior to interval debulking with survival in patients treated 
by neoadjuvant chemotherapy. 
MATERIALS AND METHODS
The records of all advanced ovarian, primary peritoneal and 
tubal carcinoma patients who after diagnosis had initial che­
motherapy during the period 2000­2010, were abstracted 
after institutional review board approval. The diagnosis of ma­
lignancy in these patients was confirmed by cytology exami­
nation of ascitic fluid and/or by core biopsy. Patients were al­
located to neoadjuvant chemotherapy according to Nelson’s 
CT criteria [10] i.e., mainly in the presence of ex  ten  sive disease 
in the upper abdomen and/or disease outside the peritoneal 
cavity. Their clinical and outcome data were recorded. Neoad­
juvant and post­interval debulking chemotherapy consisted 
of intravenous paclitaxel (175 mg/m
2) and carboplatin (AUC 6) 
for three 21­day cycles. 
Results of CT imaging at diagnosis and prior to interval 
debulking were interpreted and compared by a certified 
roentgenologist (IU) who was unaware of the outcome. Two 
pa  rameters where assessed: the change of the dia  meter and 
number of abnormal findings, especially in the areas consid­
ered to be non­debulkable, and the change in the amount of 
ascites. Evaluation of response was based on RECIST criteria 
[19]. In brief according to RECIST criteria complete response 
(CR) is defined as disappearance of all target lesions. Partial 
response (PR) is defined as at least a 30% decrease in the sum 
of diameters of target lesions, and stable disease (SD) is when 
there is neither sufficient shrinkage to qualify for PR nor suf­
ficient increase to qualify for progressive disease. 
In the present study the assessed variables were scored on a 
0­2 scale based (but not identical) on the RECIST criteria where 
0 represented no improvement (SD according to RECIST), 1 
represented some improvement (PR according to RECIST), and 
2 represented marked improvement i.e., a reduction of more 
than 50% in the number and/or the size of the CT findings 
and no or only minimal presence of ascitic fluid (less stringent 
than CR according to RECIST). 
In addition the CA­125 level at diagnosis and its level prior to 
interval debulking were recorded. A CA­125 decrease to <35 
U/mL was considered as normalization. The percent reduc­
tion of CA­125 levels from the value at diagnosis to the value 
prior of interval debulking was also calculated. An assessment 
of PFS, i.e., the time between the last course of post interval 
debulking chemotherapy and the time of recurrence, and an 
assessment of survival was made according to the change in 
CT imaging results, according to CA­125 normalization and 
according to the percent reduction of CA­125 levels. PFS and 
overall survival were assessed by the Kaplan­Meier method 
and differences by the log­rank test. Patients with recurrence 
were treated by a large number [4­7] and dissimilar treatment 
lines and by a variety of chemotherapeutic agents. 
RESULTS
Initial chemotherapy was given to 48 patients. Of the total 
group 11 patients did not undergo interval debulking ­2 ex­
pired prior to surgery of concurrent diseases, 3 refused surgery 
and 6 had progressive disease. The study group thus compris­
es 37 consecutive patients (29 with ovarian carcinoma, 6 with 
primary peritoneal carcinoma and 2 with tubal carcinoma) 
who were managed by the neoadjuvant approach and under­
went interval debulking. All tumors were of the papillary se­
rous type. The mean age of the patients was 64.1±10.6 years 
(range, 38 to 81 years). Additional selected characteristics of 
the patients are presented in Table 1. The largest percentage 
of patients was in the 60­69 age group. The majority of the pa­
tients presented with abdominal pain and/or distention, and 
had stage IIIC grade 3 tumors. More than half of the patients 
had no visible macroscopic disease after interval debulking 
surgery and more than half where defined as platinum sensi­
tive i.e. recurrence occurred more than 6 months after the end Can imaging prior to interval debulking predict survival?
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of primary treatment. 
When compared to the CT at diagnosis, the CT prior to in­
terval debulking showed no demonstrable improvement, 
some improvement and marked improvement in 2 (5.4%), 16 
(43.2%) and 19 (51.4%) patients, respectively. Since there were 
only 2 patients with no improvement, they were combined 
with those with some improvement for the purpose of further 
analysis. No ascites was present at diagnosis in 7 patients. In 
all the remaining 30 study group patients a marked improve­
ment in the amount of ascites was observed. Normalization 
of CA­125 was found in 16 (43.2%) and a reduction greater 
than 90% was found in 24 (64.9%) of the patients. A decrease 
of more than 50% of CA­125 levels was observed in all pa­
tients. The PFS according to improvement of CT findings is 
presented in Fig. 1. The median PFS of the study group was 7.9 
months. The PFS of the patients with no/some improvement 
and of those with marked improvement was 7.93 and 7.23 
respectively (p=0.89; 95% CI, 0.55 to 1.99). The median survival 
of the patients was 49.2 months (mean, 36.9±23.8 months). 
The median survival of those with no/some improvement and 
of those with marked improvement was 45.8 months and 52.5 
months respectively (p=0.95; 95% CI, 0.41 to 2.09).
Table 2 presents the association of CA­125 response with 
PFS and with survival. No statistically significant difference was 
found between the different categories of CA­125 response.
DISCUSSION
To the best of our knowledge the association between the 
improvement of imaging findings prior to interval debulking 
surgery with survival has not been reported until now. 
We found that the median PFS of patients with marked im­
provement in the size and number of abnormal findings was 
similar to those with less favorable imaging results, and that 
marked improvement in the amount of ascites was present in 
Table 1. Selected characteristics of the patients who underwent in­
terval debulking
Characteristic No. %
Total 37 100.0
Age distribution
    ≤50   3 8.1
    50­59   8 21.6
    60­69 16 43.3
    70+ 10 27.0
Presenting symptom
    Abdominal pain/distention 25 67.6
    Gastrointestinal   3 8.1
    Other   9 24.3
Stage*
    IIIC 31 83.8
    IV   6 16.2
Grade
    2   3  8.1
    3 29 78.4
    Not recorded   5 13.5
Residual disease (cm)
    None 23 62.2
    <0.5   9 24.3
    0.5­2   3 8.1
    >2   2 5.4
Platinum sensitive
    Yes 22 59.6
    No 13 35.0
    Not yet assessable   2 5.4
*According to computed tomography findings.
Table 2. Association of CA­125 response with progression free 
survival (PFS) (n=37)
CA­125 No. % Median PFS p­value
Normalization (<35 U/mL)  0.2
  Yes 16 43.2 10.5
  No 21 56.8 3.6
Percent reduction (%)* 0.3
  ≥90 24 64.9 7.9
  <90 13 35.1 5.3
*The percent reduction of CA­125 levels from the value at diagnosis 
to the value prior of interval debulking.
Fig. 1. Progression­free survival according to improvement of compu­
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all patients. Our study therefore indicates that imaging results 
prior to interval debulking surgery cannot be used for predic­
tion of PFS. This holds true for survival as well. However, we 
feel that it is less relevant because of the heterogeneous man­
agement of the patients subsequent to recurrence. 
It is noteworthy that the PFS of our patients is of shorter 
duration and that the median survival is longer compared to 
those reported by Vergote et al. [9] (7.9 vs. 12 months and 49.2 
vs. 30 months, respectively). The differences can be attributed 
to our small number of patients. Although the patients were 
informed after 3 treatment cycles that the chance of response 
to additional treatment is slim, they all requested and received 
multiple additional treatment cycles. Whether the longer sur­
vival of our patients is due to the administration of the large 
number (up to 7) of treatment lines, is questionable. Indeed 
recent evidence suggests that more number of cycles does 
not improve the outcome [20]. 
The rate of patients in our series with no residual disease 
after interval debulking (62%) is in the range of that reported 
by Vergote et al. [9] and Brun et al. [21] (50% and 73%, respec­
tively). 
Only four previous studies attempted to compare variables 
at diagnosis with the same variables after neoadjuvant che­
motherapy and prior to interval debulking surgery in order to 
investigate whether improvement in these variables might 
predict outcome. In two studies Le et al. reported that normal­
ization, defined as a reduction in serum CA­125 levels to less 
than 35 U/mL, in 16 patients with elevated levels at diagnosis 
[15] and that a decrease of at least 50% from baseline prior to 
interval debulking surgery [16] were found not to be indepen­
dent predictors of either progression­free or overall survival. 
In contrast, in a third study, CA­125 regression coefficient was 
calculated and found to be a significant prognostic factor for 
overall survival [17]. This study was criticized [15] because the 
definition of the response using a CA­125 regression coef­
ficient was not a standard one and difficult to reproduce, and 
because in the majority of patients significant cytoreductive 
surgery was not attempted. In an additional study, in vitro 
tumor cloning assay results regarding platinum or paclitaxel 
resistance of 22 ovarian cancer patients treated with neoadju­
vant chemotherapy were assessed and were also found not to 
be predictive of PFS [18]. The results of our study, namely the 
lack of association of PFS and survival with CA­125 normaliza­
tion and with the percent CA­125 reduction, are in line with 
those reported by Le et al. [15,16].
The ability to predict the outcome after neoadjuvant chemo­
therapy prior to interval debulking is important for two main 
reasons. It is of great prognostic significance and it may iden­
tify patients who might have an unfavorable prognosis thus 
allowing a more rational planning of further management. 
This could include additional treatment with different chemo­
therapeutic agents prior or after interval debulking or to forgo, 
after informed consent, interval debulking with its inherent 
morbidity.
It seems that neither improvement in imaging results nor 
CA­125 level response can predict the outcome after neoadju­
vant chemotherapy prior to interval debulking. We are aware 
of the small size of our series (post hock power of only about 
10%), and that our results should be confirmed in a larger 
study. Whether a larger series would yield a different result re­
mains to be proven. Since positron emission tomography (PET) 
is an indicator of the metabolic state of malignancies it is pos­
sible that PET­CT could be a more accurate imaging modality 
to predict the outcome prior to interval debulking. However, 
this remains to be investigated. 
Further studies are indicated in order to find a method that 
will enable prediction of outcome after neoadjuvant chemo­
therapy and prior to interval debulking. 
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